

# Q1 2023 Conference Call

Anita Johansen, CEO Henrik Lundkvist, CFO

Lund, 26<sup>th</sup> April 2023

## **Safe Harbor Statement**

This presentation contains certain forward-looking information that reflects Probi's present view of future events, as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information. Given the risks associated with forward-looking statements, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. Probi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

Probi does not make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. Probi does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.








- **1 Executive Overview**
- **2** Financial Review
- 3 Outlook
- 4 Q&A




# Positive one-off effects contributed to growth

- Net sales increased by 11% (2% adjusted for currency effects) to SEK 172 m (155) in Q1. Positive one-off effects of SEK 18 m from postponed orders in Q4.
- The EBITDA margin amounted to 28% (25) in Q1.

- Underlying market in Americas shows signs of slowing down.
- EMEA impacted by sell-out of stock by former distributor in Sweden as a consequence of Probi taking over distribution in-house.
- APAC delivered an all-time high net sales in Q1 with good help from timing of orders. China is the driving force in APAC and has high growth potential.
- First order containing BLIS strains delivered in China and first batch of sporeforming probiotic produced
- Changes in executive management, Anita Johansen permanent CEO and appointment of new VP Operations.











- **1 Executive Overview**
- **2** Financial Review
- 3 Outlook
- 4 Q&A



### Positive one-off effects contribute to growth




### **Net Sales and Gross Profit by region**



### Higher sales volumes improve net income

### **Reconciliation of net income** SEK m




Key aspects

- Net income increased by SEK 5 m compared to previous year explained by higher sales volumes
- Increased OpEx mainly FX related




### Solid cash flow from operations

#### **Reconciliation of group liquidity** SEK m



#### **Key aspects**


- Gross operating cash flow of SEK 47 m
- Negative working capital effect
- Paid taxes of SEK 4 m
- CapEx of SEK 14 m mainly due to investments in production facilities
- Financing includes payments of lease obligations





### Solid balance sheet with no external loans

#### Balance sheet as per Mar 31, 2023 SEK m




#### Key aspects

- Total equity of SEK 1 426 m
- No external loans
- Equity ratio 90%







- **1 Executive Overview**
- 2 Financial Review
- 3 Outlook
- 4 Q&A



### My agenda for 2023

- Building a strong leadership team
- Increase growth and profitability
- Launch new innovations
- Manufacturing excellence



- **1 Executive Overview**
- 2 Financial Review
- 3 Outlook
- 4 Q&A





## **Financial calendar**

Annual General Meeting Payment date for dividend Interim report Q2 2023 Interim report Q3 2023 Year-end report 2023 May 4, 2023 May 11, 2023 July 18, 2023 October 24, 2023 January 26, 2024

